ARS Pharmaceuticals (SPRY) EBT Growth (1y) (2021 - 2026)
ARS Pharmaceuticals (SPRY) EBT Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -0.10% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1,140.26% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 71.54% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.15% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 88.57% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | -156.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -156.94% |
| Dec 31, 2025 | -192.39% |
| Sep 30, 2025 | 27.30% |
| Jun 30, 2025 | -229.75% |
| Mar 31, 2025 | 58.93% |
| Dec 31, 2024 | 571.87% |
| Sep 30, 2024 | 98.99% |
| Jun 30, 2024 | 99.82% |
| Mar 31, 2024 | 99.77% |
| Dec 31, 2023 | 33.83% |
| Sep 30, 2023 | -101,915.07% |
| Jun 30, 2023 | -282,138.23% |
| Mar 31, 2023 | -339,646.93% |
| Dec 31, 2022 | -132.07% |
| Sep 30, 2022 | 65.88% |
| Jun 30, 2022 | 90.73% |
| Mar 31, 2022 | 39.92% |
| Dec 31, 2021 | 449.32% |
| Sep 30, 2021 | -422.12% |
| Jun 30, 2021 | -2,029.83% |